Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Core Insights - Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases [3] - The company will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 [1] Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines targeting kidney and metabolic diseases, including obesity [3] - The company operates its Compass™ platform to pursue genetically validated targets, integrating variant discovery and functionalization [3] - Maze's leading pipeline products include MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [3] Event Information - A live webcast of the upcoming presentation will be available on the Maze Therapeutics website and archived for 60 days [2]